ERBB2 and breast cancer: In addition to HER2 monoclonal antibody drugs, including trastuzumab and pertuzumab, several small-molecule tyrosine kinase inhibitors, such as lapatinib, neratinib and pyrotinib, and an antibody-drug conjugate (T-DM1) have emerged for HER2+ breast cancer treatment in recent years.